Vistusertib

Solid Malignancies

AstraZenecaSmall moleculePhase 1Dormant

CC

46/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 32/ 100
Competitive Position: 89/ 100

Competitive context

1412 Active assets in the Solid Malignancies cohort.

Asset / Sponsor	Phase	Rating
Nabiximols Jazz Pharmaceuticals	Phase 3	BBB
Inno-206 M.D. Anderson Cancer Center	Phase 2	BB
Vitamin B6 M.D. Anderson Cancer Center	Phase 4	BB
PROPOFOL Hong Kong Children's Hospital	Phase 4	BB
Rivoceranib Jiangsu HengRui Medicine Co., Ltd.	Phase 4	BB

View all 50 →

Same molecule, other indications

Vistusertib is also rated in:

diffuse large B-cell lymphomaDormant

B

Indicative ·

62 / 100

small cell lung carcinomaDormant

B

Indicative ·

56 / 100

breast cancerDormant

B

Indicative ·

56 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.